193 related articles for article (PubMed ID: 12027807)
21. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
[TBL] [Abstract][Full Text] [Related]
22. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
23. Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIalpha.
Syrovets T; Büchele B; Gedig E; Slupsky JR; Simmet T
Mol Pharmacol; 2000 Jul; 58(1):71-81. PubMed ID: 10860928
[TBL] [Abstract][Full Text] [Related]
24. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.
Robinson MJ; Corbett AH; Osheroff N
Biochemistry; 1993 Apr; 32(14):3638-43. PubMed ID: 8385484
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of DNA topoisomerase II catalytic activity by the antiviral agents 7-chloro-1,3-dihydroxyacridone and 1,3,7-trihydroxyacridone.
Vance JR; Bastow KF
Biochem Pharmacol; 1999 Aug; 58(4):703-8. PubMed ID: 10413309
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the clastogenic, DNA intercalative, and topoisomerase II-interactive properties of bioflavonoids in Chinese hamster V79 cells.
Snyder RD; Gillies PJ
Environ Mol Mutagen; 2002; 40(4):266-76. PubMed ID: 12489117
[TBL] [Abstract][Full Text] [Related]
27. Biological evaluation of a halogenated triterpenoid, 2α-bromo-dihydrobelulonic acid as inhibitor of human topoisomerase IIα and HeLa cell proliferation.
Ghosh S; Mukhopadhyay S; Sarkar M; Mandal A; Das V; Kumar A; Giri B
Chem Biol Interact; 2017 Apr; 268():68-76. PubMed ID: 28254521
[TBL] [Abstract][Full Text] [Related]
28. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons.
D'Arpa P; Beardmore C; Liu LF
Cancer Res; 1990 Nov; 50(21):6919-24. PubMed ID: 1698546
[TBL] [Abstract][Full Text] [Related]
29. beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin.
Li CJ; Averboukh L; Pardee AB
J Biol Chem; 1993 Oct; 268(30):22463-8. PubMed ID: 8226754
[TBL] [Abstract][Full Text] [Related]
30. An insight into the mechanism of inhibition of unusual bi-subunit topoisomerase I from Leishmania donovani by 3,3'-di-indolylmethane, a novel DNA topoisomerase I poison with a strong binding affinity to the enzyme.
Roy A; Das BB; Ganguly A; Bose Dasgupta S; Khalkho NV; Pal C; Dey S; Giri VS; Jaisankar P; Dey S; Majumder HK
Biochem J; 2008 Jan; 409(2):611-22. PubMed ID: 17922678
[TBL] [Abstract][Full Text] [Related]
31. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
32. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
Sorensen M; Sehested M; Jensen PB
Mol Pharmacol; 1999 Mar; 55(3):424-31. PubMed ID: 10051525
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of DNA synthesis and DNA fragmentation in stimulated splenocytes by the concerted action of topoisomerase I and II poisons.
Taudou G; Portemer C; Jaxel C; Duguet M
Biochem Pharmacol; 1993 Jan; 45(2):331-7. PubMed ID: 8382059
[TBL] [Abstract][Full Text] [Related]
34. Study of antioxidant effect of apigenin, luteolin and quercetin by DNA protective method.
Romanová D; Vachálková A; Cipák L; Ovesná Z; Rauko P
Neoplasma; 2001; 48(2):104-7. PubMed ID: 11478688
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of human DNA topoisomerase IB by a cyclometalated gold III compound: analysis on the different steps of the enzyme catalytic cycle.
Castelli S; Vassallo O; Katkar P; Che CM; Sun RW; Desideri A
Arch Biochem Biophys; 2011 Dec; 516(2):108-12. PubMed ID: 22033340
[TBL] [Abstract][Full Text] [Related]
36. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
Ellis AL; Nowak B; Plunkett W; Zwelling LA
Cancer Chemother Pharmacol; 1994; 34(3):249-56. PubMed ID: 8004759
[TBL] [Abstract][Full Text] [Related]
37. DNA topoisomerase II inhibition by peroxisomicine A(1) and its radical metabolite induces apoptotic cell death of HL-60 and HL-60/MX2 human leukemia cells.
Lansiaux A; Laine W; Baldeyrou B; Mahieu C; Wattez N; Vezin H; Martinez FJ; Piñeyro A; Bailly C
Chem Res Toxicol; 2001 Jan; 14(1):16-24. PubMed ID: 11170504
[TBL] [Abstract][Full Text] [Related]
38. Flavonoids as DNA topoisomerase I poisons.
López-Lázaro M; Martín-Cordero C; Toro MV; Ayuso MJ
J Enzyme Inhib Med Chem; 2002 Feb; 17(1):25-9. PubMed ID: 12365457
[TBL] [Abstract][Full Text] [Related]
39. Catalytic inhibition of topoisomerase IIalpha by demethylzeylasterone, a 6-oxophenolic triterpenoid from Kokoona zeylanica.
Furbacher TR; Gunatilaka AA
J Nat Prod; 2001 Oct; 64(10):1294-6. PubMed ID: 11678653
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of replicon initiation in human cells following stabilization of topoisomerase-DNA cleavable complexes.
Kaufmann WK; Boyer JC; Estabrooks LL; Wilson SJ
Mol Cell Biol; 1991 Jul; 11(7):3711-8. PubMed ID: 1646393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
